Investigational AlloCAR T™ products are designed to overcome limitations of autologous therapies and deliver these transformative treatments to more patients where they seek care. $ALLO #CART #celltherapy #immunotherapy

Join us for our Q1 2024 conference call on Monday, May 13 at 2:00 p.m. PT / 5:00 p.m. ET. A webcast will be available on the investor section of our website. $ALLO ir.allogene.com/news-releases/…

Yesterday Allogene celebrated its 6th anniversary! Thank you to all of our dedicated employees for their hard work and commitment to our mission – bringing the first allogeneic CAR T product to cancer and autoimmune patients. $ALLO

An incredible and well-deserved honor! Congratulations to you both. Ellen Sigal Friends of Cancer Research

Allogene has received a $15M grant from the California Institute for Regenerative Medicine (CIRM) for our investigational 'off-the-shelf' CAR T product for solid tumors, ALLO-316, for patients with renal cell carcinoma (RCC).

Learn more here >> ir.allogene.com/news-releases/…

We’re pioneering a new approach to LBCL treatment with our groundbreaking ALPHA3 trial that aims to identify and treat patients as part of the 1L regimen, potentially transforming the standard of care. $ALLO #CART #celltherapy #Immunotherapy

David Chang, MD, PhD, President, and CEO of Allogene will join a panel next Monday at the virtual Canaccord Horizons in Oncology Conference. Watch the webcast in the investors section of our website. #CART #celltherapy #immunotherapy

Congratulations to Owen Witte, MD, on receiving the AACR Award for Outstanding Achievement in Blood Cancer Research.

At Allogene, we’ve rewritten the CAR T playbook. Our approach to development and trial design has the potential to deliver ‘off-the-shelf’ CAR T products that do what autologous CAR T therapies cannot. $ALLO #CART #celltherapy #immunotherapy

Allogeneic CAR T has the potential to redefine the future of CAR T. Learn how we are leveraging the unique attributes of investigational AlloCAR T™ products to meet the current and future needs of patients and dramatically expand access to treatment. allogene.com

New $BMY Breyanzi approval comes at a timely moment for $ALLO
oncologypipeline.com/apexonco/new-b…

Pleased to report our Q4 and Full Year 2023 corporate update and business highlights.
ir.allogene.com/news-releases/…

Allogene Therapeutics and Arbor Biotechnologies will use their allogeneic CAR T and next-generation gene-editing platforms to develop novel off-the-shelf CAR-T therapies for autoimmune diseases.
#cart #pharma #biospace
hubs.li/Q02pg06Z0

We are pleased to announce our collaboration with @ArborTx for use of their CRISPR gene-editing technology to develop allogeneic CAR T products for autoimmune disease. #CART $ALLO #celltherapy #immunotherapy ir.allogene.com/news-releases/…

Read more about how investigational allogeneic CAR T products are going where autologous therapies can not. $ALLO #CART #celltherapy #immunotherapy
statnews.com/sponsor/2024/0…

Join us for our Q4 and full year 2023 conference call on Thursday, March 14 at 2:00 p.m. PT / 5:00 p.m. ET. A webcast will be available on the investor section of our website. $ALLO ir.allogene.com/news-releases/…

David Chang, MD, PhD, President and CEO of Allogene will join the Allogeneic Cell Therapy panel discussion this Wednesday at the TD Cowen 44th Annual Healthcare Conference. Watch the webcast in the investors section of our website. $ALLO #CART #celltherapy #immunotherapy

Today at the #LiquidBiopsySummit Paul Robbins, our VP of Translational Science, will discuss the role of #MRD testing to determine eligibility in ALPHA3, a novel trial for first line consolidation treatment of LBCL using allogeneic #CART . #ForesightDiagnostics $ALLO

Join our CEO David Chang at the Oppenheimer Healthcare Life Sciences Conference on Wednesday, February 14 at 12:00pm EST where he'll discuss our efforts to generate more competitive CAR T products and expand the market. Listen here: ir.allogene.com/events

Join us Wednesday, February 7 at 11:30 am EST for the Guggenheim Biotechnology Conference where our Head of R&D Dr. Zachary Roberts will share Allogene's plans to redefine the future of CAR T. Listen to the live or archived chat here: ir.allogene.com/events/event-d…